Vivos Inc. (RDGL)
OTCMKTS · Delayed Price · Currency is USD
0.1030
+0.0080 (8.42%)
Aug 22, 2025, 4:00 PM EDT
Vivos Revenue
Vivos had revenue of $15.00K in the quarter ending June 30, 2025, with 11.11% growth. This brings the company's revenue in the last twelve months to $51.74K, up 106.97% year-over-year. In the year 2024, Vivos had annual revenue of $28.00K with 43.56% growth.
Revenue (ttm)
51.74K
Revenue Growth
+106.97%
P/S Ratio
903.35
Revenue / Employee
51.74K
Employees
1
Market Cap
46.74M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.00K | 8.50K | 43.56% |
Dec 31, 2023 | 19.50K | -17.00K | -46.57% |
Dec 31, 2022 | 36.50K | 21.61K | 145.17% |
Dec 31, 2021 | 14.89K | 7.89K | 112.67% |
Dec 31, 2020 | 7.00K | -2.50K | -26.32% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Vivos News
- 9 days ago - Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA - GlobeNewsWire
- 5 weeks ago - Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic - GlobeNewsWire
- 3 months ago - Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™ - GlobeNewsWire
- 4 months ago - Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 - GlobeNewsWire
- 4 months ago - Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 8 months ago - Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide - GlobeNewsWire
- 8 months ago - Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial - GlobeNewsWire
- 11 months ago - Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - GlobeNewsWire